Analyst Research
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Finlabo SIM Spa
|
$58.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Grifols SA Acquires 60% Stake In Progenika Biopharma SA
Grifols SA announced that it has acquired shares of Progenika Biopharma SA, representing 60% stake in the company. Total price of the stake amounts to EUR 37 million. Moreover, Grifols SA and shareholders of Progenika Biopharma SA have been reciprocally granted rights to buy and sell shares, representing the remaining 35% of the capital, exercisable within 3 years.
Latest Developments for Grifols SA
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Grifols SA Signs Deal To License Aradigm Corp's Pulmaquin; May Buy 35% Stake In Aradigm Corp-Reuters
- Standard & Poor’s Upgrades Its Ratings On Grifols SA
- Moody's Investors Service Upgrades Its Ratings On Grifols SA- Reuters
Latest Key Developments in Pharmaceuticals
- Share this
- Link this
- Digg this
Follow Reuters